Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A macrocyclic peptide complement C5 inhibitor FDA-approved for generalized myasthenia gravis. One of the newest peptide drugs, representing the cutting edge of peptide therapeutics in autoimmune disease.
A thymic peptide that plays a central role in immune system regulation. Approved as a drug in over 35 countries (though not in the US) for hepatitis B and C treatment and as an immune booster.
Binds to complement component C5, preventing its cleavage into C5a and C5b, thereby blocking the terminal complement cascade and formation of the membrane attack complex (MAC). This reduces complement-mediated destruction of the neuromuscular junction in myasthenia gravis.
Enhances T-cell function, promotes dendritic cell maturation, and modulates cytokine production. Acts as an immune system regulator rather than a simple stimulant, helping to balance immune responses.
- Generalized myasthenia gravis (anti-AChR antibody positive)
- Immune system support
- Chronic infection management
- Cancer adjunct therapy (in some countries)
- Post-illness recovery
- Autoimmune condition management
- Increased risk of meningococcal infections (requires vaccination)
- Injection site reactions
- Upper respiratory infections
- Diarrhea
- Requires daily self-injection
- Generally well-tolerated in clinical use
- Injection site reactions
- Rare allergic reactions
- May interact with immunosuppressive drugs
FDA-approved as Zilbrysq (2023) for generalized myasthenia gravis in adults who are anti-acetylcholine receptor antibody positive. First subcutaneous complement inhibitor — previous options (eculizumab) required IV infusion.
Reclassified to Category 1 in February 2026 as part of the HHS announcement restoring compounding access. Not affected by the April 15, 2026 Category 2 removal action. Approved as Zadaxin in 35+ countries but not FDA-approved in the US. Available through licensed 503A compounding pharmacies with a physician prescription.
- Zilucoplan in generalized myasthenia gravis (RAISE)
2023 · PubMed
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.